Codelivery of BCL2 and MCL1 Inhibitors Enabled by Phenylboronic Acid‐Functionalized Polypeptide Nanovehicles for Synergetic and Potent Therapy of Acute Myeloid Leukemia

Abstract Acute myeloid leukemia (AML) is the most refractory hematologic malignancy characterized by acute onset, rapid progression, and high recurrence rate. Here, codelivery of BCL2 (ABT199) and MCL1 (TW37) inhibitors using phenylboronic acid‐functionalized polypeptide nanovehicles to achieve syne...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Jiguo Xie, Xiaofei Zhao, Peng Zhang, Yueyue Zhang, Ru Cheng, Zhiyuan Zhong, Chao Deng
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Wiley 2023-03-01
Serie:	Advanced Science
Soggetti:	acute myeloid leukemia BCL2 inhibitor BN coordination boronic ester bond MCL1 inhibitor synergetic therapy
Accesso online:	https://doi.org/10.1002/advs.202204866
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!